| 王玉珏,彭 冲,李玉杰,刘明军,王思奎,孙桂荣.血清CD163、AFU、miR202在原发性肝癌诊断中的作用及在介入治疗前后的变化[J].,2021,(12):2363-2367 |
| 血清CD163、AFU、miR202在原发性肝癌诊断中的作用及在介入治疗前后的变化 |
| Role of Serum CD163, AFU and Mir202 in Diagnosis of Primary Liver Cancer and Their Changes Before and After Interventional Therapy |
| 投稿时间：2020-12-05 修订日期：2020-12-28 |
| DOI：10.13241/j.cnki.pmb.2021.12.036 |
| 中文关键词: 原发性肝癌 诊断 介入治疗 CD1663 α-L-岩藻糖苷酶 miR202 |
| 英文关键词: Primary liver cancer Diagnosis Interventional therapy CD1663 α-L- fucosidase miR202 |
| 基金项目:青岛大学医学部"临床医学+X"工程面上项目（2018-31）；山东省自然科学基金项目（ZR2011HQ250） |
|
| 摘要点击次数: 821 |
| 全文下载次数: 454 |
| 中文摘要: |
| 摘要 目的：探讨血清CD163、α-L-岩藻糖苷酶（AFU）、微小核糖核酸202（miR202）在原发性肝癌诊断中的作用及在介入治疗前后的变化。方法：选择本院2018年5月~2020年6月收治的106例原发性肝癌患者，均予以肝动脉化疗栓塞术（TACE）治疗，同期选择本院收治的94例肝硬化患者纳入疾病对照组，门诊健康体检者113例纳入健康对照组。对比三组血清CD163、AFU、miR202，原发性肝癌患者治疗前后CD163、AFU、miR202。结果：原发性肝癌组血清CD163、AFU高于疾病对照组及健康对照组，差异有统计学意义（P<0.05），miR202低于对照组及健康对照组（P<0.05）；疾病对照组血清CD163、AFU高于健康对照组（P<0.05），miR202低于健康对照组（P<0.05）。原发性肝癌患者治疗后血清CD163、AFU低于治疗前，差异有统计学意义（P<0.05）；miR202高于治疗前，差异有统计学意义（P<0.05）。治疗前及治疗后，好转组血清CD163、AFU水平均低于无效组，差异有统计学意义（P<0.05），miR202高于无效组，差异有统计学意义（P<0.05）；治疗后，好转组血清CD163、AFU水平低于治疗前（P<0.05），miR202高于治疗前（P<0.05），无效组治疗前后血清CD163、AFU、miR202差异无统计学意义（P>0.05）。结论：血清CD163、AFU、miR202能够辅助原发性肝癌的诊断，又可为TACE的疗效评价提供参考依据。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the role of serum CD163, α-L- fucosidase (AFU) and MicroRNA 202(miR202) in the diagnosis of primary liver cancer and their changes before and after interventional therapy. Methods: 106 patients with primary liver cancer admitted to our hospital from May 2018 to June 2020 were treated by transcatheter arterial chemoembolization (TACE). At the same time, 94 patients with liver cirrhosis admitted to our hospital were selected to be included in the disease control group, and 113 outpatients were included in the healthy control group. Serum CD163, AFU, miR202 were compared among the three groups, and CD163, AFU, miR202 in patients with primary liver cancer before and after treatment. Results: Serum CD163 and AFU in primary liver cancer group were higher than those in disease control group and healthy control group (P<0.05), and miR202 was lower than those in control group and healthy control group(P<0.05); Serum CD163 and AFU in disease control group were higher than those in healthy control group(P<0.05), and miR202 was lower than that in healthy control group(P<0.05). Serum CD163 and AFU in patients with primary liver cancer after treatment were lower than those before treatment, and the difference was statistically significant(P<0.05). miR202 was higher than that before treatment, and the difference was statistically significant(P<0.05). Before and after treatment, the levels of serum CD163 and AFU in the improved group were lower than those in the ineffective group(P<0.05), and miR202 was higher than that in the ineffective group(P<0.05). After treatment, the levels of serum CD163, AFU in improved group were lower than those before treatment(P<0.05), and miR202 was higher than that before treatment(P<0.05). There was no significant difference in serum CD163, AFU, miR202 in ineffective group before and after treatment(P>0.05). Conclusion: Serum CD163, AFU and miR202 can assist the diagnosis of primary liver cancer, and can also provide reference for evaluating the curative effect of TACE. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
